Innate Pharma Income Statement (2018-2025) | IPHA

Income Statement Dec2018 Dec2019 Jun2020 Dec2020 Jun2021 Dec2021 Jun2022 Dec2022 Jun2023 Dec2023 Jun2024 Dec2024 Jun2025
Revenue & cost
Revenue 76.35M66.95M13.86M18.57M50.58M41.69M55.84M14.12M13.49M
Operating items
Research & Development -87.27M-59.27M-53.77M-0.05M-60.28M-55.55M
Selling, General & Administrative -28.56M-22.64M-29.20M-0.02M-19.68M-21.07M
Other Operating Expenses 0.00
Operating Expenses -115.83M-81.90M-82.97M-0.08M-79.95M-76.61M
Operating Income -54.71M
EBIT -54.71M
Non-operating items
Interest & Investment Income 0.00M
Non Operating Income -2.27M-557.06
Net income details
EBT -54.71M
Profit After Tax 3.48M-22.98M-76.29M57.13M-60.41M-0.06M-8.14M53.34M-52.86M48.32M
Income from Continuing Operations -54.71M
Consolidated Net Income -75.30M-52.03M-0.06M-8.14M-52.86M
Income towards Parent Company -75.30M-52.03M-0.06M-8.14M-52.86M
Net Income towards Common Stockholders -75.30M-52.03M-0.06M-8.14M-52.86M
Additional items
EPS (Basic) -0.96-0.650.00-0.10-0.65
Shares Outstanding (Weighted Average) 74.71M74.71M78.58M78.58M78.99M79.54M79.54M79.89M79.54M80.45M80.97M80.97M83.83M
Shares Outstanding (Diluted Average) 86.90M95.13M85.10M87.46M87.09M98.41M
EBITDA -54.71M
Shares Outstanding 58.46M66.75M58.91M58.00M34.63M18.92M